Impax Laboratories Inc. today announced that it is commencing shipment of authorized generic TRILIPIX® (fenofibric acid) delayed release capsules 45 mg and 135 mg through Global Pharmaceuticals Impax’s generics division.
Under the terms of a settlement agreement Abbott Laboratories (now AbbVie Inc.) and Fournier Laboratories Ireland Ltd. granted Impax the right to sell an authorized generic as early as July 15 2013.
According to IMS Health (NSP) U.S. sales of TRILIPIX® 45 mg and 135 mg were approximately $549 million for the 12 months ended May 2013.
About Impax Laboratories Inc.
Impax Laboratories Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally where strategically appropriate Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies such as injectables nasal sprays inhalers patches creams and ointments. For more information please visit the Company’s Web site at: www.impaxlabs.com.
